Evidence map›Paper›PMID 29967151›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Repurposing isoxazoline veterinary drugs for control of vector-borne human diseases.

Marie Miglianico, Maarten Eldering, Hannah Slater, Neil Ferguson, Pauline Ambrose, Rosemary S Lees, Karin M J Koolen, Katerina Pruzinova, Magdalena Jancarova, Petr Volf and 12 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Antimalarial drug discovery: progress and approaches.Nature reviews. Drug discovery · 2023
    Review
  16. Article
  17. Fluralaner (BravectoParasites & vectors · 2023
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 8 institutions in 4 countries.

Marie MiglianicoTropIQ Health Sciences, 6534 Nijmegen, The Netherlands.ORCID 0000-0001-6893-3745
Maarten ElderingTropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
Hannah SlaterMRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London SW7 2AZ, United Kingdom.
Neil FergusonMRC Centre for Outbreak Analysis and Modelling, Department of Infectious Disease Epidemiology, Imperial College London, London SW7 2AZ, United Kingdom.
Pauline AmbroseThe Liverpool Insect Testing Establishment, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom.
Rosemary S LeesThe Liverpool Insect Testing Establishment, Liverpool School of Tropical Medicine, Liverpool L3 5QA, United Kingdom.
Karin M J KoolenTropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
Katerina PruzinovaDepartment of Parasitology, Faculty of Science, Charles University, 116 36 Prague, Czech Republic.
Magdalena JancarovaDepartment of Parasitology, Faculty of Science, Charles University, 116 36 Prague, Czech Republic.
Petr VolfDepartment of Parasitology, Faculty of Science, Charles University, 116 36 Prague, Czech Republic.
Constantianus J M KoenraadtLaboratory of Entomology, Wageningen University and Research, 6700 Wageningen, The Netherlands.
Hans-Peter DuerrNumerus Ltd., RG40 2AY Tübingen, Germany.
Graham TrevittXenoGesis Ltd., Nottingham NG1 1GF, United Kingdom.
Baiyuan YangCalifornia Institute for Biomedical Research, La Jolla, CA 92037.
Arnab K ChatterjeeCalifornia Institute for Biomedical Research, La Jolla, CA 92037.ORCID 0000-0001-5171-7982
John WislerCalifornia Institute for Biomedical Research, La Jolla, CA 92037.
Angelika SturmTropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
Teun BousemaDepartment of Medical Microbiology, Radboud University Medical Center, 6525 Nijmegen, The Netherlands.
Robert W SauerweinTropIQ Health Sciences, 6534 Nijmegen, The Netherlands.
Peter G SchultzCalifornia Institute for Biomedical Research, La Jolla, CA 92037; schultz@calibr.org mtremblay@calibr.org k.dechering@tropiq.nl.
Matthew S TremblayCalifornia Institute for Biomedical Research, La Jolla, CA 92037; schultz@calibr.org mtremblay@calibr.org k.dechering@tropiq.nl.
Koen J DecheringTropIQ Health Sciences, 6534 Nijmegen, The Netherlands; schultz@calibr.org mtremblay@calibr.org k.dechering@tropiq.nl.
California Institute for Biomedical Research · USTropIQ Health Sciences · NLCharles University · CZImperial College London · GBLiverpool School of Tropical Medicine · GBRadboud University Nijmegen · NLNexor (United Kingdom) · GBWageningen University & Research · NL

Funding

Models for synthesising molecular, clinical and epidemiological data, and translaU01GM110721 · NIGMS · IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE · PI CAUCHEMEZ, SIMON, FERGUSON, NEIL MORRIS · 2014 to 2018
$1.9M
Medical Research Council MR/R015600/1NIGMS NIH HHS U01 GM110721
6 · The paper itself

Abstract

Isoxazolines are oral insecticidal drugs currently licensed for ectoparasite control in companion animals. Here we propose their use in humans for the reduction of vector-borne disease incidence. Fluralaner and afoxolaner rapidly killed

Indexed as

AnimalsCommunicable Disease ControlCulicidaeHumansInsecticidesMosquito ControlMosquito VectorsPsychodidaeInsecticidesinsecticideisoxazolinemalariavector controlzika fever

Identifiers

PMID29967151
PMCPMC6055183
OpenAlexW2809905673

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.